ISTA Pharmaceuticals (ISTA) falls 27.6% after reporting Q2 revenue and adjusted EPS of $37.1M...


ISTA Pharmaceuticals (ISTA) falls 27.6% after reporting Q2 revenue and adjusted EPS of $37.1M (+6% Y/Y) and -$0.11, below a consensus of  $41.9M and $0.05. Perhaps more importantly, ISTA is also reporting that a a Phase 3 study for its REMURA drug for treating dry eye disease showed that the drug "was not statistically significantly better" than a placebo.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs